8ee55a63-4e87-4c00-8012-4c87efdcb7ed
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 74
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- UV_RESPONSE_DN+0.410
- ANGIOGENESIS+0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.290
- PROTEIN_SECRETION+0.270
- KRAS_SIGNALING_UP+0.240
- ANDROGEN_RESPONSE+0.210
- SPERMATOGENESIS+0.200
- PANCREAS_BETA_CELLS+0.190
- BILE_ACID_METABOLISM+0.180
- HEME_METABOLISM+0.150
Top 10 suppressed
- MYC_TARGETS_V2-0.560
- MYC_TARGETS_V1-0.490
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.440
- DNA_REPAIR-0.410
- UNFOLDED_PROTEIN_RESPONSE-0.400
- E2F_TARGETS-0.380
- TNFA_SIGNALING_VIA_NFKB-0.370
- G2M_CHECKPOINT-0.300
- MTORC1_SIGNALING-0.300
- INTERFERON_ALPHA_RESPONSE-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-50-5944-01A-11R-1755-07 | — | cohortA1 | 0.832 |
| 2 | TCGA-D6-6824-01A-11R-1915-07 | — | — | 0.811 |
| 3 | SRR8613742 | — | A | 0.807 |
| 4 | f8877925-49e4-420e-8bd8-cac3a47b67d1 | — | — | 0.795 |
| 5 | SRR12475118 | — | — | 0.793 |
| 6 | TCGA-K4-A3WU-01B-11R-A23N-07 | — | — | 0.789 |
| 7 | C3L-03268 | — | cohortA1 | 0.789 |
| 8 | 65f86d9a-828b-4e8b-a656-38baba5a54f7 | — | — | 0.788 |
| 9 | TCGA-D8-A1XO-01A-11R-A14M-07 | — | B | 0.788 |
| 10 | TCGA-86-8668-01A-11R-2403-07 | — | cohortA1 | 0.787 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UV_RESPONSE_DN | 0.410 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.290 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.270 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.240 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.210 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.190 | Cobimetinib | — uncovered |
| BILE_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.150 | Temsirolimus | — uncovered |
| COMPLEMENT | 0.140 | Inavolisib | — uncovered |
| MYOGENESIS | 0.140 | Inavolisib | — uncovered |
| COAGULATION | 0.100 | Binimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.090 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.060 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.030 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.030 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.020 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.020 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.010 | Inavolisib | — uncovered |